Toggle light / dark theme

Have a good day group 😅.


On Thursday, Donald Trump raised a few eyebrows as he spoke at the White House daily briefing on the coronavirus. Like us previously He reportedly suggested using UV lights or injecting disinfectants into a person affected by the virus.

Oddly enough, Trump’s suggestion not only sparked a conversation, as many people ignored him, but also prompted RB, the makers of Lysol and Dettol, to release a statement to assure everyone that their products are NOT for internal use, despite Trump’s suggestion.

On Friday, the company released the statement in its official website and said: “As a world leader in health and hygiene products, we must be clear that under no circumstances should our disinfectant products be administered to the human body (by injection, ingestion, or any other route). As with all products, our disinfectant products and hygiene should only be used as intended and in accordance with usage guidelines. Read label and safety information. We have a responsibility to provide consumers with access to accurate and up-to-date information as advised by leading health experts public ”.

In the constant battle against the spread of infectious diseases, scientists are continually on the hunt for new weapons that specifically target pathogenic microbes. Now, investigators from the Center for Radiological Research at Columbia University Irving Medical Center (CUIMC) believe they may have found a new, low-cost solution to eradicating airborne viruses in indoor public spaces. The research team found that continuous low doses of far ultraviolet C (far-UVC) light can kill airborne flu viruses without harming human tissues. The findings from the new study—published today in Scientific Reports in an article entitled “Far-UVC Light: A New Tool to Control the Spread of Airborne-Mediated Microbial Diseases”—suggests that use of overhead far-UVC light in hospitals, doctors’ offices, schools, airports, airplanes, and other public spaces could provide a powerful check on seasonal influenza epidemics, as well as influenza pandemics.

Scientists have known for decades that broad-spectrum UVC light, which has a wavelength of between 200 to 400 nanometers (nm), is highly effective at killing bacteria and viruses by destroying the molecular bonds that hold their DNA together. This conventional UV light is routinely used to decontaminate surgical equipment.

“Unfortunately, conventional germicidal UV light is also a human health hazard and can lead to skin cancer and cataracts, which prevents its use in public spaces,” explained senior study investigator David Brenner, Ph.D., director of the Center for Radiological Research and professor at CUIMC.

April 2020


The COVID-19 pandemic caused by SARS-CoV-2 has brought about an unprecedented crisis, taking a heavy toll on human health, lives as well as the global economy. There are no SARS-CoV-2-specific treatments or vaccines available due to the novelty of this virus. Hence, rapid development of effective vaccines against SARS-CoV-2 is urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies potently neutralized 10 representative SARS-CoV-2 strains, indicative of a possible broader neutralizing ability against SARS-CoV-2 strains circulating worldwide. Immunization with two different doses (3μg or 6 μg per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without any antibody-dependent enhancement of infection. Systematic evaluation of PiCoVacc via monitoring clinical signs, hematological and biochemical index, and histophathological analysis in macaques suggests that it is safe. These data support the rapid clinical development of SARS-CoV-2 vaccines for humans.

One Sentence Summary A purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc) confers complete protection in non-human primates against SARS-CoV-2 strains circulating worldwide by eliciting potent humoral responses devoid of immunopathology.

The authors have declared no competing interest.

On March 16, Moderna and the National Institute of Allergy & Infectious Diseases (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.

Without placing too much significance on this, it is a good sign, suggesting that the trial is progressing well and there are no obvious bad side effects from the first round.

Lisa Jackson, senior investigator, Kaiser Permanente Washington Health Research Institute, who is heading the study, told USA Today that the physicians at Kaiser Permanente’s Vaccine Treatment and Evaluation Unit in Seattle don’t have results from the first round. This suggests that the study data is blinded, meaning it will not be released until a specific point in the trial.

This is the truth of the looming “hunger pandemic,” which has the potential to engulf over a quarter of a billion people whose lives and livelihoods will be plunged into immediate danger, unless urgent and effective action is taken to keep commercial and humanitarian goods flowing, support communities with humanitarian assistance and provide governments with the additional health interventions required to control the spread of the virus.


If we can’t reach these people — if we can’t give them the lifesaving assistance they need because our funding has been cut or borders where we move our food have been closed — WFP’s analysis shows that 300,000 could starve to death every single day for the next three months.

When you consider that already, despite our best efforts, 21,000 people die of hunger every single day, the scale of the potential death toll is heart-rending. We could be looking at famine in about three dozen countries. In 10 countries, we have more than a million people who are on the verge of starvation as we speak.

Strokes, seizures, loss of smell and taste and other neurological deficits are showing up in patients critically ill with the coronavirus.

Although the virus is classified as a respiratory disorder and primarily damages the lungs, clinicians are seeing patients with a wide array of symptoms, from seizures to hallucinations, brain inflammation, disorientation, delirium and loss of smell and taste.

“I had a patient, a young guy, 48, who attended a party in New Rochelle two weeks before and came in with hallucinations and confusion,” said Dr. Pooia Fattahi, regional chair of neurology for Trinity Health Of New England. The patient had no fever and only a slight cough. Still, aware some COVID-19 patients show up at hospitals with seizures, strokes and confusion, Fattahi suspected, correctly, that the patient had COVID-19. Three of those who attended the same New Rochelle party ultimately died of the virus.

The Rockefeller Foundation releases an ambitious new proposal to test 30 million people a week, employ up to 300,000 contact tracers, and establish a digital data sharing platform. Rajiv Shah, President and CEO of the Rockefeller Foundation, and Dr. Kavita Patel, former health policy director in the Obama White House, join Andrea Mitchell to discuss this and other plans to reopen the country. April 22, 2020.

:ooooo.


At the beginning of March, Democratic Gov. Gavin Newsom of California announced a series of executive orders he hoped would help slow the spread, and subsequently mitigate the health impact, of COVID-19. One of those orders told Golden State residents to shelter-in-place. This order, set for two weeks, has been extended until May. Gov. Newsom has subsequently told residents that the process through which these public health safety measures will be loosened up is going to be deliberate, and done by degrees.

A study out of UC Davis in California says there is one silver lining to the shelter-in-place orders, though. According to researchers, the California highway patrol—who on average respond to more than 2,000 roadway “incidents” per day—have reported an enormous reduction in the daily rate of collisions. This means a lot less death and injury and a lot of public money saved.

UC Davis researchers found that the daily rate of collisions in California was cut in half after the order, and that cut closely matched the reduction in deaths and injuries connected to vehicular crashes. To this end, the study found that trauma centers reported a 40% reduction in people seen during this time, which includes pedestrians and cyclists involved in vehicular collisions. The savings to the public is estimated at about $40 million per day, adding up to around $1 billion in savings since the beginning of the shelter-in-place order.

What do you think about.this?


Coronavirus patients taking hydroxychloroquine, a treatment touted by President Trump, were no less likely to need mechanical ventilation and had higher deaths rates compared to those who did not take the drug, according to a study of hundreds of patients at US Veterans Health Administration medical centers.

The study, which reviewed veterans’ medical charts, was posted Tuesday on medrxiv.org, a pre-print server, meaning it was not peer reviewed or published in a medical journal. The research was funded by the National Institutes of Health and the University of Virginia.